Tumor News and Research

RSS

Duke University researchers devise new method for making potential nanoscale cancer treatment

In a move akin to adding chemical weapons to a firebomb, researchers at Duke University have devised a method for making a promising nanoscale cancer treatment even more deadly to tumors.

14 Jul 2015

Cedars-Sinai's groundbreaking online registry improves participation in clinical research

Research for Her, Cedars-Sinai's groundbreaking online registry that matches women with research studies and clinical trials, enrolled study participants more quickly when compared with traditional paper-based registries, according to new research published in the journal Gynecologic Oncology.

14 Jul 2015

Biosimilars show promise for children with IBD, but more research needed

Children with inflammatory bowel disease (IBD) who are doing well on specific biological medications should not be switched to recently approved "biosimilar" products, concludes an expert consensus statement of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.

14 Jul 2015

Researchers identify genetic abnormalities that lead to skin SCC

Squamous cell carcinoma (SCC) of the skin is one of the most frequent cancers in humans affecting more than half million new persons every year in the world. The transformation of a normal cell to a cancer cell is caused by an accumulation of genetic abnormalities in the progeny of single cells. The spectrum of genetic anomalies found in a variety of human cancers have been described.

14 Jul 2015

New understanding of keratin 17 protein could lead to development of better ways to prevent cancer

New research from the Johns Hopkins Bloomberg School of Public Health suggests that the protein keratin 17 - the presence of which is used in the lab to detect and stage various types of cancers - is not just a biomarker for the disease, but may play a critical role in tumor growth.

14 Jul 2015

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

US-Australian drug discovery company, Novogen Limited, today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

14 Jul 2015

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

QIAGEN N.V. today received U.S. marketing (PMA) approval of its therascreen EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca's IRESSA (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC).

From QIAGEN Manchester Limited 14 Jul 2015

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).

13 Jul 2015

Accuray, RaySearch sign long-term collaboration agreement for RayCare oncology information system

Accuray Incorporated and RaySearch Laboratories AB (publ) announced today they have signed a long-term collaboration agreement which will allow Accuray to co-market and offer the RayCare oncology information system (OIS) which is currently in development at RaySearch.

13 Jul 2015

OncoGenex's custirsen Phase 3 ENSPIRIT trial for treatment of NSCLC patients continues as planned

OncoGenex Pharmaceuticals, Inc. announced today that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is continuing as planned per the recommendation of an Independent Data Monitoring Committee (IDMC). This decision was based upon completion of the second and final planned interim futility analysis.

13 Jul 2015

Three European medical centers planning upgrades to Elekta's stereotactic radiosurgery system for the brain

Three foremost medical centers in the United Kingdom and Germany have ordered and are now planning upgrades to Elekta's latest generation stereotactic radiosurgery system for the brain, Leksell Gamma Knife Icon, to provide the most advanced brain radiosurgery treatments for their patients.

From Elekta 13 Jul 2015

MPI applications: an interview with Tobias Knopp, University Hospital Hamburg

Up to now, we've seen a lot of improvements made, but now we're almost at the point of focusing on the application of MPI and proving what the real benefits of this technology are, which is very exciting...

From Bruker BioSpin - NMR, EPR and Imaging 12 Jul 2015

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

12 Jul 2015

Turnstone announces ongoing enrollment of Marabex clinical trial

Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours.

12 Jul 2015

Cedars-Sinai scientists identify genes responsible for tumor growth in high grade brain tumors

After generating new brain tumor models, Cedars-Sinai scientists in the Board of Governors Regenerative Medicine Institute identified the role of a family of genes underlying tumor growth in a wide spectrum of high grade brain tumors.

10 Jul 2015

Researchers identify five recurrent fusion genes involved in acute gastritis and cancer

Studying the gastric cancers of 15 Southeast Asian patients, researchers at The Jackson Laboratory, the Genome Institute of Singapore and other institutions identified five recurrent fusion genes, one of which appears to lead to cellular changes involved in acute gastritis and cancer.

10 Jul 2015

Four young scientists named recipients of Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award

The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award, committing nearly $875,000 to help address a critical shortage of funding for pediatric cancer research.

10 Jul 2015

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the US National Cancer Institute, a world-leading institute for cancer research, today announced that they have implemented two-way linking between research articles on ScienceDirect and datasets stored in NCI's cancer Nanotechnology Laboratory (caNanoLab) data portal.

9 Jul 2015

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics.

9 Jul 2015

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Sorrento Therapeutics, Inc. and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of 'first-in-class' small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells.

9 Jul 2015

Tumor News and Research

Duke University researchers devise new method for making potential nanoscale cancer treatment

Cedars-Sinai's groundbreaking online registry improves participation in clinical research

Biosimilars show promise for children with IBD, but more research needed

Researchers identify genetic abnormalities that lead to skin SCC

New understanding of keratin 17 protein could lead to development of better ways to prevent cancer

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Accuray, RaySearch sign long-term collaboration agreement for RayCare oncology information system

OncoGenex's custirsen Phase 3 ENSPIRIT trial for treatment of NSCLC patients continues as planned

Three European medical centers planning upgrades to Elekta's stereotactic radiosurgery system for the brain

MPI applications: an interview with Tobias Knopp, University Hospital Hamburg

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Turnstone announces ongoing enrollment of Marabex clinical trial

Cedars-Sinai scientists identify genes responsible for tumor growth in high grade brain tumors

Researchers identify five recurrent fusion genes involved in acute gastritis and cancer

Four young scientists named recipients of Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News